Pharmacists in Falmouth, KY Accepting Medicare
7 Pharmacists found. Showing 1 - 7
 Jayna Patel, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1100 W Shelby St, Falmouth, KY 41040 Phone: 859-654-3232 Fax: 859-654-3277 |
Danielle Yelton Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1100 W Shelby St, Falmouth, KY 41040 Phone: 859-654-3232 |
 Mr. Ronald Lee Moreland, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 509 Chapel St, Falmouth, KY 41040 Phone: 859-654-3964 |
Joyce Kramer, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1100 W Shelby St, Falmouth, KY 41040 Phone: 859-654-3232 |
Jesse Bates, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1157 Ridgeway Ave, Falmouth, KY 41040 Phone: 859-654-3383 |
James Derek Wheeler Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1157 Ridgeway Ave, Falmouth, KY 41040 Phone: 859-654-3383 Fax: 859-654-4080 |
Brett Ramsey, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1100 W Shelby St, Falmouth, KY 41040 Phone: 859-654-3232 Fax: 859-654-3277 |
News Archive
People with low incomes are more likely to develop brain cancer
People with low incomes are more likely to develop brain cancer, according to a study published in the May 25 issue of Neurology, the scientific journal of the American Academy of Neurology.
Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV
Medivir AB, announced today plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen's protease inhibitor simeprevir and Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135.
YODA Project enters an agreement with Johnson & Johnson to gain access to clinical trial data assets
In a move that promotes open science, the Yale University Open Data Access (YODA) Project has entered an agreement with Johnson & Johnson that will enable scientists around the world to gain access to the company's clinical trial data assets.
Taking strong anticholinergic doubles risk of developing cognitive impairment in older adults
Research from the Regenstrief Institute, the Indiana University Center for Aging Research and Wishard-Eskenazi Health on medications commonly taken by older adults has found that drugs with strong anticholinergic effects cause cognitive impairment when taken continuously for as few as 60 days.
› Verified 8 days ago